260 related articles for article (PubMed ID: 21882256)
1. PPP2R1A mutations are common in the serous type of endometrial cancer.
Nagendra DC; Burke J; Maxwell GL; Risinger JI
Mol Carcinog; 2012 Oct; 51(10):826-31. PubMed ID: 21882256
[TBL] [Abstract][Full Text] [Related]
2. Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.
Shih IeM; Wang TL
J Pathol; 2011 May; 224(1):1-4. PubMed ID: 21432855
[TBL] [Abstract][Full Text] [Related]
3. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
McConechy MK; Anglesio MS; Kalloger SE; Yang W; Senz J; Chow C; Heravi-Moussavi A; Morin GB; Mes-Masson AM; ; Carey MS; McAlpine JN; Kwon JS; Prentice LM; Boyd N; Shah SP; Gilks CB; Huntsman DG
J Pathol; 2011 Apr; 223(5):567-73. PubMed ID: 21381030
[TBL] [Abstract][Full Text] [Related]
4. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
5. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
[TBL] [Abstract][Full Text] [Related]
6. Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Haesen D; Abbasi Asbagh L; Derua R; Hubert A; Schrauwen S; Hoorne Y; Amant F; Waelkens E; Sablina A; Janssens V
Cancer Res; 2016 Oct; 76(19):5719-5731. PubMed ID: 27485451
[TBL] [Abstract][Full Text] [Related]
7. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas.
Shih IeM; Panuganti PK; Kuo KT; Mao TL; Kuhn E; Jones S; Velculescu VE; Kurman RJ; Wang TL
Am J Pathol; 2011 Apr; 178(4):1442-7. PubMed ID: 21435433
[TBL] [Abstract][Full Text] [Related]
10. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features.
Bartosch C; Manuel Lopes J; Oliva E
Adv Anat Pathol; 2011 Nov; 18(6):415-37. PubMed ID: 21993268
[TBL] [Abstract][Full Text] [Related]
11. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
12. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
[TBL] [Abstract][Full Text] [Related]
13. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
Xiong Y; Dowdy SC; Xue A; Shujuan J; Eberhardt NL; Podratz KC; Jiang SW
Gynecol Oncol; 2005 Mar; 96(3):601-9. PubMed ID: 15721400
[TBL] [Abstract][Full Text] [Related]
14. Targeted mutation analysis of endometrial clear cell carcinoma.
Hoang LN; McConechy MK; Meng B; McIntyre JB; Ewanowich C; Gilks CB; Huntsman DG; Köbel M; Lee CH
Histopathology; 2015 Apr; 66(5):664-74. PubMed ID: 25308272
[TBL] [Abstract][Full Text] [Related]
15. Molecular analysis in endometrial cancer.
Caduff RF; Svoboda-Neumann SM; Johnston CM; Bartos RE; Frank TS
Verh Dtsch Ges Pathol; 1997; 81():219-27. PubMed ID: 9474873
[TBL] [Abstract][Full Text] [Related]
16. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
17. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease.
Kupryjanczyk J; Thor AD; Beauchamp R; Poremba C; Scully RE; Yandell DW
Mod Pathol; 1996 Mar; 9(3):166-73. PubMed ID: 8685209
[TBL] [Abstract][Full Text] [Related]
18. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
19. Infrequent mutations of the PPP2R1A and PPP2R1B genes in patients with ovarian cancer.
Wang F; Zou Y; Liu FY; Yu XH; Huang H; Zhang N; Qi YY; Liu RF; Liu XY; Chen J; Huang OP; He M
Mol Med Rep; 2013 Jun; 7(6):1826-30. PubMed ID: 23588898
[TBL] [Abstract][Full Text] [Related]
20. Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.
Bashir S; Jiang G; Joshi A; Miller C; Matrai C; Yemelyanova A; Caputo TA; Holcomb KM; Ellenson LH; Gupta D
Int J Gynecol Cancer; 2014 Sep; 24(7):1262-7. PubMed ID: 25078343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]